Alterity Gets FDA Nod To Conduct Phase 2 Trial Of ATH434 In Multiple System Atrophy

By RTTNews Staff Writer ✉ | Published: 9/20/2022 8:14 AM ET

Alterity Therapeutics Ltd. (ATHE), a company focused on neurodegenerative diseases, said on Tuesday that it has received FDA clearance to conduct a phase II clinical trial of ATH434 in Multiple System Atrophy.

Multiple System Atrophy or MSA, is a rare and highly debilitating Parkinsonian disorder.

The phase II clinical trial will explore the effect of ATH434 treatment on neuroimaging and protein biomarkers, such as excess brain iron and aggregating a-synuclein, which are important contributors to MSA pathology. The study is expected to enroll approximately 60 adult patients.

Alterity expects to open its first clinical trial site for enrolment next quarter (Q4, 2022).

For comments and feedback contact: editorial@rttnews.com

Business News

Biotech Stocks Facing FDA Decision In March 2023

Biotech Stocks Facing FDA Decision In February 2023

Biotech stocks Facing FDA Decision in January 2023

Editors Pick

United Airlines, Archer To Launch First Air Taxi Route In Chicago

United Airlines and Archer Aviation Inc. announced plans to launch the first commercial electric air taxi route in Chicago, between O'Hare International Airport or ORD and Vertiport Chicago. As part of their urban air mobility or UAM network buildout, both companies will utilize Archer's electric vertical takeoff and landing or eVTOL aircraft in the new route.

Aunt Millie's Our Family White Hot Dog Buns Recalled

Fort Wayne, Indiana-based Perfection Bakeries D/B/A Aunt Millie's is recalling 8 ct. packages of Our Family White Hot Dog Buns citing the possible presence of undeclared sesame, a known allergen, the U.S. Food and Drug Administration said. The product comes in a printed plastic package marked with "Our Family Hot Dog Buns 8 ct." on the top and has a blue twist tie.

Ascend Labs Recalls Oral Anticoagulant Dabigatran Etexilate Capsules

Parsippany, New Jersey -based Ascend Laboratories LLC. is recalling Dabigatran Etcxilate capsules citing the detection of N-Nitrosodimethylamine or NDMA impurity, a probable human carcinogen, the U.S. Food and Drug Administration said. The product is used as an oral anticoagulant to lower the risk of stroke and blood clots.

Latest Updates on COVID-19

34% Fall In US Covid Cases, 38% Fall In Deaths In Last 2 Weeks

Biden Signs Covid Origins Bill Into Law

FDA Authorizes Bivalent Pfizer Covid Vaccine As Booster Dose For Select Children Under 5

Covid Cases, Hospitalizations Fall Nationwide In Last 2 Weeks

FDA Authorizes First At-Home Test To Detect Flu And COVID-19

COVID-19: Drugs in Development

Follow RTT

Most Read
Most Emailed

Alterity Gets FDA Nod To Conduct Phase 2 Trial Of ATH434 In Multiple System Atrophy

Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing

Accenture Sees Higher Q3 Revenues; Cuts FY23 Earnings, Sales Growth View - Update

FDA Clears Eat Just's Good Meat Cultivated Chicken

United Airlines, Archer To Launch First Air Taxi Route In Chicago

Pearson In Deal To Sell Pearson Online Learning Services To Regent

Foot Locker Q4 Profit Down, Warns On FY23; To Close Hong Kong Operations

Zai Lab Partner Karuna's Phase 3 Trial Of KarXT In Schizophrenia Meets Primary Endpoint

Ascend Labs Recalls Oral Anticoagulant Dabigatran Etexilate Capsules

TUI Group To Increase Capital By EUR 1.8 Bln To Repay Debt, Cut Costs

Knight-Swift To Acquire U.S. Xpress Enterprises For Enterprise Value Of $808 Mln

PDD Holdings Q4 Profit Rises 43%

Illumina: Icahn's Director Nominees Do Not Add Value To Board

Novartis: SMA Drug Zolgensma Long-term Data Shows Sustained Durability Up To 7.5 Years Post-dosing

Spectris Commences Third Tranche Of Share Repurchase Programme

Sandoz Gets FDA Approval For Biosimilar Hyrimoz High-concentration Formulation

Shoe Carnival Q4 GAAP Net Income Rises

TUI Group To Increase Capital By EUR 1.8 Bln To Repay Debt, Cut Costs

Death Toll Linked To Contaminated Eye Drops Rises To Three

Semtech Enters Into Cooperation Agreement With Lion Point Capital - Quick Facts

Accenture plc Q2 Profit Decreases, but beats estimates

Bytes Technology Sees Higher FY23 Results; Stock Up

TELUS Prices $500mln Of Senior Unsecured Notes With 10-year Maturity

Gambling.com Q4 Earnings - Update

Recon Technology Posts Loss In H1; Total Revenues Down 16.3%